First line hormone therapy vs chemotherapy for HR+HER2-metastatic breast cancer in the phase III STIC CTC trial: clinical choice and validity of CTC count

Affiliation auteurs!!!! Error affiliation !!!!
TitreFirst line hormone therapy vs chemotherapy for HR+HER2-metastatic breast cancer in the phase III STIC CTC trial: clinical choice and validity of CTC count
Type de publicationJournal Article
Year of Publication2016
AuteursBidard F-C., Brain E., Jacot W., Bachelot T., Ladoire S., Bourgeois H., Gonalves A., Naman H., Gligorov J., Dalenc F., Levy C., Espie M., Ferrero J-M., Luporsi E., Sablin M-P., Dubot C., Chevrier M., Berger F., Alix-Panabieres C., Pierga J-Y.
JournalANNALS OF ONCOLOGY
Volume27
Date PublishedOCT 1
Type of ArticleMeeting Abstract
ISSN0923-7534
DOI10.1093/annonc/mdw365.5